Choosing the best contraceptive method for the adult with congenital heart disease

Current Cardiology Reports

Volumn 11, Issue 4, 2009, Pages 298-305

  Silversides, Candice K ^a   Sermer, Mathew ^a   Siu, Samuel C ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; DEPO SUBQ PROVERA; ESTROGEN; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; UNCLASSIFIED DRUG; WARFARIN;

ARTERY THROMBOSIS; BLOOD PRESSURE; BLOOD TRANSFUSION; CARDIOMYOPATHY; CONGENITAL HEART DISEASE; CONTRACEPTION; CONTRACEPTIVE DEVICE; COUNSELING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EISENMENGER COMPLEX; FEMALE; FLUID RETENTION; FONTAN PROCEDURE; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEART VALVE PROSTHESIS; HEART VENTRICLE FUNCTION; HEMATOMA; HORMONAL CONTRACEPTION; HUMAN; HYPERTENSION; INTRAUTERINE CONTRACEPTIVE DEVICE; LOW DRUG DOSE; LUNG EMBOLISM; MEDICAL DECISION MAKING; MENSTRUAL IRREGULARITY; NAUSEA AND VOMITING; OVULATION; PRACTICE GUIDELINE; PREGNANCY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; THROMBOEMBOLISM; THROMBUS; TREATMENT INDICATION; UTERINE TUBE LIGATION; UTERUS BLEEDING; VASECTOMY; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, HORMONAL; COUNSELING; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; RISK ASSESSMENT; RISK FACTORS; WORLD HEALTH ORGANIZATION;

EID: 67650251495     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-009-0043-7     Document Type: Review

References (44)

1. Warnes CA, Williams RG, Bashore TM, et al.: ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008, 118:e714-e833.
2. Siu SC, Sermer M, Colman JM, et al.: Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001, 104:515-521.
3. Siu SC, Colman JM: Heart disease and pregnancy. Heart 2001, 85:710-715.
4. Uebing A, Steer PJ, Yentis SM, Gatzoulis MA: Pregnancy and congenital heart disease. BMJ 2006, 332:401-406.
5. Drenthen W, Pieper PG, Roos-Hesselink JW, et al.: Outcome of pregnancy in women with congenital heart disease: A literature review. J Am Coll Cardiol 2007, 49:2303-2311.
6. Trussel J: Contraceptive efficacy. In Contraceptive Technology, edn 18. Edited by Hatcher R, Trussel J, Stewart F, et al. New York: Ardent Media; 2004:773-845.
7. Kovacs AH, Harrison JL, Colman JM, et al.: Pregnancy and contraception in congenital heart disease: What women are not told. J Am Coll Cardiol 2008, 52:577-578.
8. Sidney S, Petitti DB, Soff GA, et al.: Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception 2004, 70:3-10.
9. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995, 346:1575-1582.
10. Jick H, Jick SS, Gurewich V, et al.: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995, 346:1589-1593.
11. Poulter NR, Chang CL, Marmot M, et al.: Third-generation oral contraceptives and venous thrombosis. Lancet 1997, 349:732.
12. Endrikat J, Klipping C, Cronin M, et al.: An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 2002, 65:215-221.
13. Oelkers W, Foidart JM, Dombrovicz N, et al.: Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995, 80:1816-1821.
14. Narkiewicz K, Graniero GR, D'Este D, et al.: Ambulatory blood pressure in mild hypertensive women taking oral contraceptives. A case-control study. Am J Hypertens 1995, 8:249-253.
15. Chasan-Taber L, Willett WC, Manson JE, et al.: Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996, 94:483-489.
16. Acute myocardial infarction and combined oral contraceptives: Results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1997, 349:1202-1209.
17. Lidegaard O: Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: The influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol 1995, 102:153-159.
18. Margolis KL, Adami HO, Luo J, et al.: A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril 2007, 88:310-316.
19. Sidney S, Siscovick DS, Petitti DB, et al.: Myocardial infarction and use of low-dose oral contraceptives: A pooled analysis of 2 US studies. Circulation 1998, 98:1058-1063.
20. World Health Organization: Medical Eligibility Criteria for Contraceptive Use, edn 3. Geneva, Switzerland: World Health Organization; 2004.
21. Gaffield ME, Curtis KM, Mohllajee AP, Peterson HB: Medical eligibility criteria for new contraceptive methods: Combined hormonal patch, combined hormonal vaginal ring and the etonogestrel implant. Contraception 2006, 73:134-144.
22. ACOG Committee on Practice Bulletins-Gynecology: ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006, 107:1453-1472.
23. Vis JC, Timmermans J, Post MC, et al.: Increased prevalence of migraine in Marfan syndrome. Int J Cardiol 2008 Aug 2 (Epub ahead of print).
24. Kiesewetter CH, Sheron N, Vettukattill JJ, et al.: Hepatic changes in the failing Fontan circulation. Heart 2007, 93:579-584.
25. Miner P: Contraceptive choices for females with congenital heart disease. Prog Pediatr Cardiol 2004, 19:15-24.
26. Canobbio MM, Perloff JK, Rapkin AJ: Gynecological health of females with congenital heart disease. Int J Cardiol 2005, 98:379-387.
27. Thorne S, Nelson-Piercy C, MacGregor A, et al.: Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam Plann Reprod Health Care 2006, 32:75-81.
28. Thorne S, MacGregor A, Nelson-Piercy C: Risks of contraception and pregnancy in heart disease. Heart 2006, 92:1520-1525.
29. Silversides CK, Granton JT, Konen E, et al.: Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol 2003, 42:1982-1987.
30. Varma C, Warr MR, Hendler AL, et al.: Prevalence of "silent" pulmonary emboli in adults after the Fontan operation. J Am Coll Cardiol 2003, 41:2252-2258.
31. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998, 57:315-324.
32. Vasilakis C, Jick H, del Mar Melero-Montes M: Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999, 354:1610-1611.
33. Conard J, Plu-Bureau G, Bahi N, et al.: Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004, 70:437-441.
34. Mohllajee AP, Curtis KM, Martins SL, Peterson HB: Hormonal contraceptive use and risk of sexually transmitted infections: A systematic review. Contraception 2006, 73:154-165.
35. Peterson HB, Xia Z, Hughes JM, et al.: The risk of pregnancy after tubal sterilization: Findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996, 174:1161-1168; discussion 1168-1170.
36. Peterson HB, Xia Z, Wilcox LS, et al.: Pregnancy after tubal sterilization with silicone rubber band and spring clip application. Obstet Gynecol 2001, 97:205-210.
37. Duffy S, Marsh FA Rogerson L, et al.: Female sterilisation: a cohort controlled comparative study of ESSURE versus laparoscopic sterilisation. BJOG 2005, 112:1522-1528.
38. Famuyide AO, Hopkins MR, El-Nashar SA, et al.: Hysteroscopic sterilization in women with severe cardiac disease: Experience at a tertiary center. Mayo Clin Proc 2008, 83:431-438.
39. Bedard E, Dimopoulos K, Gatzoulis MA: Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2009, 30:256-265.
40. Weiss BM, Zemp L, Seifert B, Hess OM: Outcome of pulmonary vascular disease in pregnancy: A systematic overview from 1978 through 1996. J Am Coll Cardiol 1998, 31:1650-1657.
41. Reid GJ, Siu SC, McCrindle BW, et al.: Sexual behavior and reproductive concerns among adolescents and young adults with congenital heart disease. Int J Cardiol 2008, 125:332-338.
42. Leonard H, O'sullivan JJ, Hunter S: Family planning requirements in the adult congenital heart disease clinic. Heart 1996, 76:60-62.
43. Rogers P, Mansour D, Mattinson A, O'sullivan JJ: A collaborative clinic between contraception and sexual health services and an adult congenital heart disease clinic. J Fam Plann Reprod Health Care 2007, 33:17-21.
44. Moons P, De Geest S, Budts W: Comprehensive care for adults with congenital heart disease: Expanding roles for nurses. Eur J Cardiovasc Nurs 2002, 1:23-28.